Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press204110.17650/1726-9776-2026-22-2-116-124REVIEWSОБЗОРЫReview ArticleFerroptosis in urologic oncology: molecular mechanisms, morphological verification, and therapeutic potentialФерроптоз в онкоурологии: молекулярные механизмы, морфологическая верификация и терапевтический потенциалhttps://orcid.org/0009-0002-1818-5077VlasovaAngelina O.ВласоваАнгелина Олеговна
Russian Federation
angvlon@mail.ruhttps://orcid.org/0000-0003-2202-7071ShchekinV. S.ЩекинВ. С.
Russian Federation
angvlon@mail.ruhttps://orcid.org/0009-0005-0062-3763TeregulovI. I.ТерегуловИ. И.
Russian Federation
angvlon@mail.ruhttps://orcid.org/0009-0004-9887-9865ValinurovT. I.ВалинуровТ. И.
Russian Federation
angvlon@mail.ruhttps://orcid.org/0000-0003-2125-4897PavlovV. N.ПавловВ. Н.
Russian Federation
angvlon@mail.ruBashkir State Medical University, Ministry of Health of RussiaФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России290920262221161242404202602062026Copyright ©; 2026, ABV-PressCopyright ©; 2026, АБВ-пресс2026ABV-PressАБВ-прессhttps://creativecommons.org/licenses/by/4.0/https://oncourology.abvpress.ru/oncur/article/view/2041

Ferroptosis is a form of regulated iron-dependent cell death driven by the accumulation of lipid peroxidation products and the disruption of redox homeostasis. This review systematizes current data on the role of ferroptosis in the pathogenesis of major urological malignancies, including prostate cancer, renal cell carcinoma, and urothelial carcinoma. The relationship between the specific metabolic profile of genitourinary tumors and their susceptibility to lipid peroxidation is analyzed. Mechanisms of ferroptosis suppression associated with androgen receptor activity, intracytoplasmic lipid metabolism, and the functioning of antioxidant defense systems are examined. Special emphasis is placed on the morphological criteria and ultrastructural features that enable the verification of ferroptosis in tumor tissue.

Ферроптоз – это вариант регулируемой железозависимой гибели клеток, обусловленный накоплением продуктов перекисного окисления липидов и нарушением редокс-гомеостаза. В обзоре систематизированы актуальные данные о роли ферроптоза в патогенезе основных онкоурологических заболеваний: рака предстательной железы, почечно-клеточного рака и рака мочевого пузыря. Проанализирована взаимосвязь между специфическим метаболическим профилем опухолей мочеполовой системы и их чувствительностью к липидной пероксидации. Рассмотрены механизмы супрессии ферроптоза, ассоциированные с активностью андрогенового рецептора, особенностями метаболизма внутрицитоплазматических липидов и функционированием систем антиоксидантной защиты. Особое внимание уделено морфологическим критериям и ультраструктурным признакам, позволяющим верифицировать ферроптоз в опухолевой ткани.

ferroptosisprostate cancerclear cell renal cell carcinomabladder cancerlipid metabolismantioxidant defenseферроптозрак предстательной железысветлоклеточный почечно-клеточный ракрак мочевого пузырялипидный обменантиоксидантная защитаМинистерство науки и высшего образования Российской ФедерацииMinistry of Science and Higher Education of the Russian FederationThe work was carried out with the financial support of the strategic leadership program “Priority 2030” of the Bashkir State Medical University, Ministry of Health of Russia.Работа выполнена при финансовой поддержке программы стратегического лидерства «Приоритет 2030» ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России.Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3): 229–63. DOI: 10.3322/caac.21834Zeng F., Nijiati S., Tang L. et al. Ferroptosis detection: from approaches to applications. Angew Chem Int Ed Engl 2023;62(35):e202300379. DOI: 10.1002/anie.202300379Zhou Q., Meng Y., Li D. et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 2024;9(1):55. DOI: 10.1038/s41392-024-01769-5Yu L., Qiu Y., Tong X. Ferroptosis in renal cancer therapy: a narrative review of drug candidates. Cancers (Basel) 2024;16(18):3131. DOI: 10.3390/cancers16183131Yan H.F., Zou T., Tuo Q.Z. et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther 2021;6:49. DOI: 10.1038/s41392-020-00428-9Vartanian A.A., Kosorukov V.S. Pro-inflammatory cytokines, ferroptosis, and cancer. Acta Naturae 2025;17(1):4–10. DOI: 10.32607/actanaturae.27547Chen X., Li J., Kang R. et al. Ferroptosis: machinery and regulation. Autophagy 2021;17(9):2054–81. DOI: 10.1080/15548627.2020.1810918Tang D., Chen X., Kang R. et al. Ferroptosis: molecular mechanisms and health implications. Cell Res 2021;31:107–25. DOI: 10.1038/s41422-020-00441-1Jiang X., Stockwell B.R., Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 2021;22:266–82. DOI: 10.1038/s41580-020-00324-8Mouawad N., El Jaafari N., El Sibai M., Abi-Habib R.J. Harnessing ferroptosis for cancer therapy: mechanisms and therapeutic strategies (review). Oncol Rep 2026;55(1):24. DOI: 10.3892/or.2025.9029Yan B., Ai Y., Sun Q. et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol Cell 2021;81(2): 355–69.e10. DOI: 10.1016/j.molcel.2020.11.024Ding X., Cui L., Mi Y. et al. Ferroptosis in cancer: revealing the multifaceted functions of mitochondria. Cell Mol Life Sci 2025;82(1):277. DOI: 10.1007/s00018-025-05812-8Sun D., Wang L., Wu Y. et al. Lipid metabolism in ferroptosis: mechanistic insights and therapeutic potential. Front Immunol 2025 Mar 11;16:1545339. DOI: 10.3389/fimmu.2025.1545339Dixon S.J., Lemberg K.M., Lamprecht M.R. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149(5):1060–72. DOI: 10.1016/j.cell.2012.03.042Galluzzi L., Vitale I., Aaronson S.A. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 2018;25(3):486–541. DOI: 10.1038/s41418-017-0012-4Mishima E., Nakamura T., Doll S. et al. Recommendations for robust and reproducible research on ferroptosis. Nat Rev Mol Cell Biol 2025;26(8):615–30. DOI: 10.1038/s41580-025-00843-2Battaglia A.M., Chirillo R., Aversa I. et al. Ferroptosis and cancer: mitochondria meet the “Iron Maiden” cell death. Cells 2020;9(6):1505. DOI: 10.3390/cells9061505Dixon S.J., Olzmann J.A. The cell biology of ferroptosis. Nat Rev Mol Cell Biol 2024;25(6):424–42. DOI: 10.1038/s41580-024-00703-5Hou W., Xie Y., Song X. et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 2016;12(8):1425–8. DOI: 10.1080/15548627.2016.1187366Torii S., Shintoku R., Kubota C. et al. An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem J 2016;473(6):769–77. DOI: 10.1042/BJ20150658Li J., Cao F., Yin H.L. et al. Ferroptosis: past, present and future. Cell Death Dis 2020;11:88. DOI: 10.1038/s41419-020-2298-2Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35(4):495–516. DOI: 10.1080/01926230701320337Bagdonaitė R., Cinar Z.O., Žvirblis R. et al. Quantitative FLIM of lipid droplet polarity with a deep-red BODIPY probe reveals signatures of ferroptosis resistance. Chem Biomed Imaging 2026;4(5):867–76. DOI: 10.1021/cbmi.5c00193Zou Y., Henry W.S., Ricq E.L. et al. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature 2020;585(7826):603–8. DOI: 10.1038/s41586-020-2732-8Bai Y., Meng L., Han L. et al. Lipid storage and lipophagy regulates ferroptosis. Biochem Biophys Res Commun 2019;508(4):997–1003. DOI: 10.1016/j.bbrc.2018.12.039Pujana-Vaquerizo M., Bozal-Basterra L., Carracedo A. Metabolic adaptations in prostate cancer. Br J Cancer 2024;131(8):1250–62. DOI: 10.1038/s41416-024-02762-zChen H., Lyu F., Gao X. Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies. Prostate Cancer Prostatic Dis 2026;29:36–46. DOI: 10.1038/s41391-024-00933-wLv D., Shi Y., Kou L. et al. Precision targeting of androgen receptor-ferroptosis crosstalk in prostate cancer: from mechanisms to therapeutic strategies. Pharmacol Res 2025;219:107915. DOI: 10.1016/j.phrs.2025.107915Yu S., Baek J., Choi T., Kim M.S. Exploiting oxidative stress as Achilles’ heel: from redox homeostasis to ferroptosis in prostate cancer. Antioxidants (Basel) 2025;14(12):1517. DOI: 10.3390/antiox14121517Cao P.H.A., Dominic A., Lujan F.E. et al. Unlocking ferroptosis in prostate cancer – the road to novel therapies and imaging markers. Nat Rev Urol 2024;21(10):615–37. DOI: 10.1038/s41585-024-00869-9Liang D., Feng Y., Zandkarimi F. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 2023;186:2748–64.e22. DOI: 10.1016/j.cell.2023.05.003Feng Y., Zhang Y., Li H. et al. Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators. Cell Death Dis 2024;15(8):559. DOI: 10.1038/s41419-024-06937-7Li B., Cheng B., Huang H. et al. Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1-FASN axis in prostate cancer. Int J Biol Sci 2024;20(12):4635–53. DOI: 10.7150/ijbs.101039Shrestha R.K., Nassar Z.D., Hanson A.R. et al. ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Res 2024;84(14):2313–32. DOI: 10.1158/0008-5472.CAN-23-1489Wang M.E., Chen J., Lu Y. et al. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis. J Clin Invest 2023;133(10):e166647. DOI: 10.1172/JCI166647Liu Q., Cong M., Gao C. et al. Targeting Hsp70 triggers ferroptosis: a novel anti-cancer mechanism of a marine natural product in prostate cancer. Nat Prod Bioprospect 2026;16:34. DOI: 10.1007/s13659-025-00586-9Zhan M., Zhao B., Chen H. et al. Metabolic reprogramming in clear cell renal cell carcinoma: core pathways and targeted therapeutic strategies. Front Genet 2026;16:1752384. DOI: 10.3389/fgene.2025.1752384Yang J., Miao D., Li X. et al. Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications. Front Cell Dev Biol 2025;13:1664292. DOI: 10.3389/fcell.2025.1664292Deng Q., Ji Y., Liu J. et al. Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting. Mol Cancer 2025;24:236. DOI: 10.1186/s12943-025-02457-wMiess H., Dankworth B., Gouw A.M. et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene 2018;37(40):5435–50. DOI: 10.1038/s41388-018-0315-zZou Y., Palte M.J., Deik A.A. et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun 2019;10:1617. DOI: 10.1038/s41467-019-09277-9Klasson T.D., LaGory E.L., Zhao H. et al. ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma. Cancer Metab 2022;10:14. DOI: 10.1186/s40170-022-00290-zHu J., Wang S.G., Hou Y. et al. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression. Nat Genet 2024;56:442–57. DOI: 10.1038/s41588-024-01662-5Li Y.C., Huang H.E., Yu C.Y. et al. Isoliensinine induces ferroptosis in urothelial carcinoma cells via the PI3K/AKT/HIF-1α axis: molecular evidence from next-generation sequencing. Pharmaceuticals (Basel) 2025;18(7):1008. DOI: 10.3390/ph18071008Yan Y., Huang Z., Zhu Z. et al. IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. Cancer Cell Int 2024;24:386. DOI: 10.1186/s12935-024-03570-4Yang Q., Zhou D., Beasley A. et al. Identification of SLC3A2 as a potential therapeutic target of ferroptosis in bladder cancer. Arch Esp Urol 2026;79(1):36–48. DOI: 10.56434/j.arch.esp.urol.20267901.5Ma X., Quan C. Identification of KIF14 as a ferroptosis biomarker for predicting the prognosis and immunotherapy efficacy of bladder cancer. Discov Oncol 2025;16:1786. DOI: 10.1007/s12672-025-03492-1Cheng X., Wang Y., Li Y. et al. Quantification of ferroptosis pattern in bladder carcinoma and its significance on immunotherapy. Sci Rep 2022;12:9066. DOI: 10.1038/s41598-022-12712-5